- $198.24bn
- $243.72bn
- $36.75bn
- 96
- 44
- 93
- 92
Annual balance sheet for Amgen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | PRESS |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8,037 | 9,305 | 10,944 | 11,973 | 9,129 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5,839 | 6,392 | 7,942 | 7,501 | 9,570 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 19,385 | 22,186 | 30,332 | 29,030 | 29,057 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5,750 | 6,006 | 6,592 | 7,100 | 7,913 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 61,165 | 65,121 | 97,154 | 91,839 | 90,586 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 12,184 | 15,687 | 18,392 | 23,099 | 25,489 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 54,465 | 61,460 | 90,922 | 85,962 | 81,928 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 6,700 | 3,661 | 6,232 | 5,877 | 8,658 |
| Total Liabilities & Shareholders' Equity | 61,165 | 65,121 | 97,154 | 91,839 | 90,586 |
| Total Common Shares Outstanding |